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BACKGROUND
Intravenous iron is a standard treatment for patients undergoing hemodialysis, but 
comparative data regarding clinically effective regimens are limited.
METHODS
In a multicenter, open-label trial with blinded end-point evaluation, we randomly as-
signed adults undergoing maintenance hemodialysis to receive either high-dose iron 
sucrose, administered intravenously in a proactive fashion (400 mg monthly, unless the 
ferritin concentration was >700 μg per liter or the transferrin saturation was ≥40%), 
or low-dose iron sucrose, administered intravenously in a reactive fashion (0 to 400 mg 
monthly, with a ferritin concentration of <200 μg per liter or a transferrin saturation 
of <20% being a trigger for iron administration). The primary end point was the com-
posite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart 
failure, or death, assessed in a time-to-first-event analysis. These end points were also 
analyzed as recurrent events. Other secondary end points included death, infection 
rate, and dose of an erythropoiesis-stimulating agent. Noninferiority of the high-dose 
group to the low-dose group would be established if the upper boundary of the 95% 
confidence interval for the hazard ratio for the primary end point did not cross 1.25.
RESULTS
A total of 2141 patients underwent randomization (1093 patients to the high-dose group 
and 1048 to the low-dose group). The median follow-up was 2.1 years. Patients in the 
high-dose group received a median monthly iron dose of 264 mg (interquartile range 
[25th to 75th percentile], 200 to 336), as compared with 145 mg (interquartile range, 100 
to 190) in the low-dose group. The median monthly dose of an erythropoiesis-stimulat-
ing agent was 29,757 IU in the high-dose group and 38,805 IU in the low-dose group 
(median difference, −7539 IU; 95% confidence interval [CI], −9485 to −5582). A total of 
320 patients (29.3%) in the high-dose group had a primary end-point event, as compared 
with 338 (32.3%) in the low-dose group (hazard ratio, 0.85; 95% CI, 0.73 to 1.00; P<0.001 
for noninferiority; P = 0.04 for superiority). In an analysis that used a recurrent-events 
approach, there were 429 events in the high-dose group and 507 in the low-dose group 
(rate ratio, 0.77; 95% CI, 0.66 to 0.92). The infection rate was the same in the two groups.
CONCLUSIONS
Among patients undergoing hemodialysis, a high-dose intravenous iron regimen ad-
ministered proactively was superior to a low-dose regimen administered reactively and 
resulted in lower doses of erythropoiesis-stimulating agent being administered. 
(Funded by Kidney Research UK; PIVOTAL EudraCT number, 2013 - 002267 - 25.)
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Patients undergoing maintenance hemodialysis usually have a negative iron balance owing to reduced absorption and 
increased blood loss.1 The intravenous adminis-
tration of iron has become standard care in the 
management of anemia, and large doses are in-
creasingly used to reduce exposure to erythro-
poiesis-stimulating agents2,3 in order to reduce 
costs and mitigate concerns about potential 
risks, particularly because of cardiovascular toxic 
effects that have been observed in trials.4-8 How-
ever, intravenous iron therapy may cause harm 
by increasing the risks of infection, oxidative 
stress, vascular calcification, and atherothrom-
bosis.9-13
Rigorous scientific evaluation of the use of 
high doses of iron in patients undergoing hemo-
dialysis has been limited, which has resulted in 
marked variation in its use among individual 
practitioners and across countries.3 We assessed 
first the noninferiority, and then the safety and 
efficacy, of a high-dose regimen of intravenous 
iron administered proactively, as compared with 
a low-dose regimen of intravenous iron admin-
istered reactively, in patients undergoing hemo-
dialysis in the Proactive IV Iron Therapy in 
Haemodialysis Patients (PIVOTAL) trial.
Me thods
Trial Design and Oversight
We conducted this prospective, randomized, open-
label, blinded end-point,14 controlled trial at 50 
sites in the United Kingdom. The trial protocol15 
(available with the full text of this article at 
NEJM.org) was approved by the relevant health 
authorities and institutional review boards, and all 
the patients provided written informed consent. 
An independent data and safety monitoring com-
mittee performed regular safety surveillance. 
Data were entered into an electronic case-report 
form by the investigators (see the Supplementary 
Appendix, available at NEJM.org) and were ana-
lyzed at the Robertson Centre for Biostatistics, 
University of Glasgow, in the United Kingdom.
This was an academic investigator–led trial. 
The trial was funded by Kidney Research UK, 
which was supported by an unrestricted grant 
from Vifor Fresenius Medical Care Renal Pharma 
(which also provided iron sucrose for the trial, 
free of charge). Vifor Fresenius Medical Care 
Renal Pharma had no input into the trial design 
or the data collection or analysis. However, the 
company was kept abreast of the progress of the 
trial by regular study reports and newsletters. 
No confidentiality agreements regarding the 
data were in place.
The initial draft of the manuscript was writ-
ten by the first author and revised by all the au-
thors. Medical writing assistance was provided 
by a professional medical writer, funded by Kid-
ney Research UK (supported by Vifor Fresenius 
Medical Care Renal Pharma). The authors had 
access to the final trial results and take respon-
sibility for the accuracy and completeness of the 
data, for the fidelity of the trial to the protocol, 
and for the decision to submit the manuscript 
for publication.
Participants
Adults with end-stage kidney disease in whom 
maintenance hemodialysis had been initiated no 
more than 12 months before the initial screen-
ing visit, who had a ferritin concentration of less 
than 400 μg per liter and a transferrin satura-
tion of less than 30%, and who were receiving 
an erythropoiesis-stimulating agent were eligible 
to participate. Any iron therapy that had been pre-
scribed previously was discontinued at the screen-
ing visit. The full eligibility criteria are provided 
in the protocol.
Randomization, Treatment, and Follow-up
Using a Web-based randomization system, we 
randomly assigned participants, in a 1:1 ratio, to 
receive a regimen of high-dose intravenous iron 
administered proactively or a regimen of low-
dose intravenous iron administered reactively; 
patients were then evaluated monthly. Random-
ization was stratified according to vascular ac-
cess (dialysis catheter vs. arteriovenous fistula or 
graft), diagnosis of diabetes (yes vs. no), and 
duration of hemodialysis treatment (<5 months 
vs. ≥5 months).
The ferritin concentration and transferrin sat-
uration were measured monthly (usually during 
the first week of the month), and these values 
determined the monthly dose of iron sucrose to be 
administered intravenously during the subsequent 
week of hemodialysis (usually the second week 
of the month). In the high-dose group, 400 mg 
of iron sucrose per month, to be administered 
intravenously, was prescribed to the patients, 
with safety cutoff limits (ferritin concentration 
of 700 μg per liter or a transferrin saturation of 
40%) above which further intravenous iron ad-
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ministration was withheld pending repeat test-
ing 1 month later. Patients in the low-dose group 
received a monthly dose of 0 mg to 400 mg of 
iron sucrose as required to maintain a minimum 
target ferritin concentration of 200 μg per liter 
and a transferrin saturation of 20%, in line with 
accepted clinical guidelines (for details of the 
iron-dosing regimen, see the Supplementary Ap-
pendix). Iron therapy was temporarily withheld 
if the trial team identified an active infection 
that was deemed by the investigator to be suf-
ficient to contraindicate the use of intravenous 
iron. Therapy was restarted when it was judged 
by the investigator to be safe to do so.
Clinicians selected the dose of erythropoiesis-
stimulating agent that would be sufficient to 
maintain a hemoglobin level of 10 to 12 g per 
deciliter.16 Apart from the dose of erythropoiesis-
stimulating agent, the trial teams treated patients 
according to standard practice.
Trial End Points
The primary end point was the composite of 
nonfatal myocardial infarction, nonfatal stroke, 
hospitalization for heart failure, or death from 
any cause, assessed in a time-to-first-event analy-
sis; definitions of the end-point events are pro-
vided in the Supplementary Appendix. The first 
secondary end point consisted of the compo-
nents of the primary end point, including first 
and repeat events, which were analyzed as recur-
rent events. Other secondary efficacy end points 
included death from any cause; the composite of 
fatal or nonfatal myocardial infarction, fatal or 
nonfatal stroke, or hospitalization for heart fail-
ure; and each of the three subcomponents of 
that end point, all assessed in time-to-first-event 
analyses. An independent committee whose mem-
bers were unaware of the trial-group assignments 
adjudicated these events according to prespeci-
fied criteria. Additional secondary efficacy end 
points included the dose of erythropoiesis-stim-
ulating agent, the incidence of blood transfu-
sion, and two quality-of-life measures (the Euro-
pean Quality of Life–5 Dimensions [EQ-5D] 
questionnaire and the Kidney Disease Quality of 
Life instrument).
Safety end points included vascular access 
thrombosis, hospitalization for any cause, and 
hospitalization for infection, each assessed in a 
time-to-first-event analysis, and the rate of epi-
sodes of infection. Laboratory tests, including the 
hemoglobin level, serum ferritin concentration, 
and transferrin saturation, were assessed month-
ly. Data on serious adverse events were collected 
prospectively, and events were coded with the 
use of the Medical Dictionary for Regulatory Activities 
(MedDRA), version 15.1. Data on nonserious ad-
verse events, other than infection and vascular 
access thrombosis, were not collected.
Statistical Analysis
In the initial sample-size calculations, we as-
sumed a 3-year event rate of 40% in the low-dose 
group and a 10% loss to follow-up (including 
loss to follow-up due to kidney transplantation). 
Thus, we estimated that a sample of 2080 pa-
tients who had 631 primary end-point events 
would provide the trial with 80% power to as-
sess the noninferiority of high-dose iron to low-
dose iron, with a noninferiority limit for the 
hazard ratio of 1.25.
Summary statistics are provided as numbers 
and percentages, as mean values with standard 
deviations, and as median values with interquar-
tile ranges (25th to 75th percentile). Treatment 
effects were estimated as the effect in the high-
dose group as compared with (or minus) the 
effect in the low-dose group, with adjustment 
for the stratification variables at randomization. 
The primary end point was analyzed first in 
terms of noninferiority in the intention-to-treat 
population, which included all the patients who 
had undergone randomization validly, with a 
supporting analysis in a per-protocol population 
that excluded patients with a major protocol vio-
lation. Analyses were censored at the date of 
kidney transplantation, withdrawal of consent, 
loss to follow-up, or transfer to home or perito-
neal dialysis, whichever came first. Noninferior-
ity was also assessed in a sensitivity analysis that 
included only patients who were currently receiv-
ing treatment, with data censored after patients 
discontinued the trial drug. The time-to-first-
event analyses were conducted with the use of 
cause-specific Cox proportional-hazards models, 
including the stratification variables and the 
treatment variable. The noninferiority analysis 
tested the null hypothesis that the hazard ratio 
for the treatment effect was at least 1.25 against 
the alternative that the hazard ratio was less than 
1.25, with a required one-sided significance level 
of 0.025. If noninferiority was established, a two-
sided superiority test (Wald statistic) was carried 
out with no penalty regarding the P value.
The incidence of death from any cause and a 
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Characteristic
Proactive, High-Dose Iron Regimen 
(N = 1093)
Reactive, Low-Dose Iron Regimen 
(N = 1048)
Age — yr 62.7±14.9 62.9±15.1
Male sex — no. (%) 710 (65.0) 688 (65.6)
Race — no. (%)†
White 868 (79.4) 830 (79.2)
Black 93 (8.5) 97 (9.3)
Asian 96 (8.8) 89 (8.5)
Other 36 (3.3) 32 (3.1)
Median duration of dialysis treatment (IQR) — mo 4.9 (2.8–8.4) 4.8 (2.8–8.1)
Vascular access — no. (%)
Dialysis catheter 449 (41.1) 428 (40.8)
Arteriovenous fistula or graft 644 (58.9) 620 (59.2)
Cardiovascular disease — no. (%)
Atrial fibrillation 96 (8.8) 68 (6.5)
Heart failure 41 (3.8) 45 (4.3)
Hypertension 804 (73.6) 753 (71.9)
Hyperlipidemia 277 (25.3) 258 (24.6)
Peripheral vascular disease 92 (8.4) 95 (9.1)
Previous myocardial infarction 97 (8.9) 87 (8.3)
Previous stroke 85 (7.8) 91 (8.7)
Diabetes — no. (%) 494 (45.2) 456 (43.5)
Smoking status — no. (%)
Current smoking 145 (13.3) 104 (9.9)
Former smoking 261 (23.9) 284 (27.1)
Never smoked 687 (62.9) 660 (63.0)
Weight — kg 81.3±21.0 82.9±20.9
Body-mass index‡ 28.5±7.1 29.0±6.7
Blood pressure — mm Hg§
Systolic 145±24 145±24
Diastolic  74±14  74±15
Hemoglobin — g/dl 10.6±1.4 10.5±1.4
Median serum ferritin concentration (IQR) — μg/liter 214 (132–305) 217 (137–301)
Median transferrin saturation (IQR) — % 20 (16–24) 20 (16–24)
Median C-reactive protein level (IQR) — mg/liter 6.0 (3.3–13.9) 7.0 (4.0–15.0)
Median dose of erythropoiesis-stimulating agent (IQR) — IU/wk¶ 8000 (5000–10,000) 8000 (5000–12,000)
Primary cause of kidney failure — no. (%)
Diabetic nephropathy 363 (33.4) 349 (33.5)
Glomerular disease 191 (17.6) 203 (19.5)
Hypertension 129 (11.9) 106 (10.2)
Tubulointerstitial disease‖ 113 (10.4) 88 (8.4)
Renovascular disease 64 (5.9) 83 (8.0)
Polycystic kidney disease 62 (5.7) 55 (5.3)
Other 61 (5.6) 68 (6.5)
Unknown 110 (10.1) 96 (9.2)
*  Plus–minus values are means ±SD. There were no significant differences between the two groups except for smoking status (P = 0.03) and the 
hemoglobin level (P = 0.04). Percentages may not total 100 because of rounding. IQR denotes interquartile range (25th to 75th percentile).
†  Race was reported by the patients.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Blood-pressure measurements were taken before hemodialysis.
¶  For darbepoetin alfa and methoxy polyethylene glycol-epoetin beta, the weekly reported dose was multiplied by 200 to convert the units from 
micrograms to international units.
‖  Tubulointerstitial disease included pyelonephritis, reflux nephropathy, and obstructive uropathy.
Table 1. Characteristics of the Patients at Baseline.*
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composite of myocardial infarction, stroke, or 
hospitalization for heart failure as recurrent 
events was analyzed with the use of the propor-
tional-means model of Lin et al.17 and described 
in the form of mean frequency functions (method 
of Ghosh and Lin).18 Other statistical methods 
and details regarding statistical assumptions are 
described in the Supplementary Appendix. The 
results for the secondary end points are reported 
as point estimates and 95% confidence intervals 
with no adjustment for multiple comparisons, so 
the confidence intervals should not be used to 
infer definitive treatment effects. The cumulative 
doses of intravenous iron were compared be-
tween the treatment groups with the use of 
Wilcoxon rank-sum tests. The statistical analysis 
plan is available with the protocol at NEJM.org.
R esult s
Patients
The trial was conducted from November 2013 
to June 2018. Of the 2589 patients who were 
screened for entry into the trial, 448 did not 
meet the criteria for randomization. A total of 
2141 patients were randomly assigned to a treat-
ment group (1093 patients to the high-dose 
group and 1048 to the low-dose group) and 
constituted the intention-to-treat population 
(Fig. S1 in the Supplementary Appendix). Follow-
up continued until June 6, 2018.
The characteristics of the patients at baseline 
were generally well balanced between the two 
treatment groups, except for smoking status 
(P = 0.03) and the hemoglobin level (P = 0.04) 
(Table 1). The prevalence of cardiovascular dis-
ease (a history of one or more of the following: 
myocardial infarction, stroke, heart failure, atrial 
fibrillation, or peripheral vascular disease) was 
29.6% in the high-dose group and 28.2% in the 
low-dose group. With the exception of angioten-
sin-converting–enzyme inhibitors or angiotensin-
receptor blockers and phosphate binders, the 
use of medications at baseline was similar in 
the two groups (Table S1 in the Supplementary 
Appendix).
Figure 1. Iron Administration over Time.
The mean cumulative doses of intravenous iron that were received by the patients in the two treatment groups are 
shown over time. Data plotted at month 0 represent the first administration of iron after randomization. At all the 
time points, patients in the group that received high-dose iron proactively received greater cumulative doses of iron 
than did the patients in the group that received low-dose iron reactively (P<0.001 for all time points). The cumula-
tive doses of iron were compared between the treatment groups with the Wilcoxon rank-sum test. I bars indicate 
95% confidence intervals.
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Excluding patients who died or underwent kid-
ney transplantation, follow-up was incomplete 
for 162 patients (14.8%) in the high-dose group 
and for 175 (16.7%) in the low-dose group (Fig. 
S1 in the Supplementary Appendix). The median 
follow-up was 2.1 years, with a maximum follow-
up of 4.4 years.
Doses of Iron and Erythropoiesis-
Stimulating Agents
The cumulative doses of intravenous iron were 
greater in the high-dose group than in the low-
dose group (Fig. 1). At month 12, the patients 
in the high-dose group had received a median 
of 2000 mg (95% confidence interval [CI], 1900 
to 2100) more iron than the patients in the low-
dose group. The median monthly dose of iron 
was 264 mg (interquartile range, 200 to 336) in 
the high-dose group and 145 mg (interquartile 
range, 100 to 190) in the low-dose group; the 
median difference in the monthly iron dose was 
121 mg (95% CI, 114 to 129). The ferritin con-
centrations and transferrin saturation both in-
creased from baseline rapidly with the high-dose 
regimen, as compared with the low-dose regimen 
(Figs. S2 and S3 in the Supplementary Appendix).
The cumulative dose of erythropoiesis-stimu-
lating agent was lower in the high-dose group 
than in the low-dose group at all the postbase-
line time points examined through 36 months 
(Fig. S4 in the Supplementary Appendix). The 
median monthly dose of erythropoiesis-stimulat-
ing agent was 19.4% lower in patients receiving 
the high-dose regimen (29,757 IU per month; 
interquartile range, 18,673 to 48,833) than in pa-
tients receiving the low-dose regimen (38,805 IU 
per month; interquartile range, 24,377 to 60,620) 
(median difference, −7539 IU per month; 95% 
CI, −9485 to −5582) (Table 2). Although patients 
in the two treatment groups had increases from 
baseline in the hemoglobin level over time, more 
rapid increases were observed in the high-dose 
group than in the low-dose group (Fig. S5 in the 
Supplementary Appendix). Plots of the median 
values and interquartile ranges of the above-
mentioned laboratory tests are shown in Figures 
S6 through S10 in the Supplementary Appendix.
Primary End Point
A primary end-point event occurred in 320 pa-
tients (29.3%) in the high-dose group, as com-
pared with 338 (32.3%) in the low-dose group * 
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(hazard ratio, 0.85; 95% CI, 0.73 to 1.00; P<0.001 
for noninferiority; P = 0.04 for superiority) 
(Fig. 2A and Table 2). Results were similar in the 
per-protocol population (hazard ratio, 0.85; 95% CI, 
0.73 to 0.99; P<0.001 for noninferiority; P = 0.04 
for superiority). The effect of high-dose iron 
therapy on the primary end point was consistent 
across all the prespecified subgroups (vascular 
access, diabetes status, and duration of dialysis 
treatment), with no significant interactions ob-
served (Fig. S11 in the Supplementary Appendix).
Secondary Efficacy End Points
There were 246 deaths (22.5% of the patients) in 
the high-dose group and 269 (25.7%) in the low-
dose group (hazard ratio, 0.84; 95% CI, 0.71 to 
1.00) (Fig. 2B and Table 2), with consistent results 
observed across the prespecified subgroups (Fig. 
S11 in the Supplementary Appendix). The rate 
of the composite of fatal or nonfatal myocardial 
infarction, fatal or nonfatal stroke, or hospital-
ization for heart failure was lower in the high-
dose group than in the low-dose group (hazard 
ratio, 0.80; 95% CI, 0.64 to 1.00). Similarly, the 
rates of the individual components of fatal or 
nonfatal myocardial infarction and hospitaliza-
tion for heart failure were lower among patients 
receiving high-dose iron than among those re-
ceiving low-dose iron (Table 2). The rate of stroke 
was similar in the two treatment groups.
Death and a composite of myocardial infarc-
tion, stroke, or hospitalization for heart failure as 
recurrent events occurred at a rate of 19.4 events 
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Figure 2. Cumulative Incidence of the Primary Efficacy 
End Point, of Death from Any Cause, and of Death 
from Any Cause and a Composite of Cardiovascular 
Events as Recurrent Events.
Panel A shows the cumulative event rates for the pri-
mary efficacy end point (a composite of death from 
any cause, nonfatal myocardial infarction, nonfatal 
stroke, and hospitalization for heart failure). Panel B 
shows the rates of death from any cause, and Panel C 
shows the rates of death from any cause and a compos-
ite of myocardial infarction, stroke, and hospitalization 
for heart failure as recurrent events plotted in the form 
of mean frequency functions with the use of the method 
of Ghosh and Lin.18 The hazard ratios (with 95% confi-
dence intervals) and rate ratio (with the 95% confidence 
interval) were adjusted for the baseline stratification 
variables of vascular access, diabetes status, and dura-
tion of dialysis treatment.
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per 100 patient-years in the high-dose group, as 
compared with 24.6 events per 100 patient-years 
in the low-dose group (rate ratio, 0.77; 95% CI, 
0.66 to 0.92) (Fig. 2C and Table 2). Patients in 
the high-dose group were less likely to receive 
blood transfusions than those in the low-dose 
group (hazard ratio, 0.79; 95% CI, 0.65 to 0.95). 
There were no significant between-group differ-
ences with regard to changes from baseline in 
either the EQ-5D quality-of-life health index or 
the Kidney Disease Quality of Life overall score.
Safety
Vascular access thrombosis occurred in 262 pa-
tients (24.0%) in the high-dose group and in 218 
(20.8%) in the low-dose group. The rates of hos-
pitalization for any cause and for infection were 
similar in the two treatment groups (Table 2). 
The rate of all episodes of infection in the high-
dose group was 63.3 events per 100 patient-years, 
as compared with 69.4 events per 100 patient-
years in the low-dose group (rate ratio, 0.91; 
95% CI, 0.79 to 1.05).
Serious adverse events occurred in 709 pa-
tients (64.9%) in the high-dose group and in 671 
(64.0%) in the low-dose group. The rates of the 
most common serious adverse events, analyzed 
according to MedDRA system organ class, were 
generally similar in the two treatment groups 
(Table 3). Infection was the most common non-
cardiovascular cause of death, and the rates were 
similar in the two treatment groups (Table S2 in 
the Supplementary Appendix).
Other End Points
High-dose iron administered proactively was asso-
ciated with a small decrease in the platelet count 
over time, as compared with a small increase in 
the group that received low-dose iron adminis-
tered reactively (Figs. S12 and S13 in the Supple-
mentary Appendix). No significant between-group 
differences were observed with regard to the 
serum albumin concentration (Figs. S14 and S15 
in the Supplementary Appendix).
Discussion
In contrast to results from observational stud-
ies,19-24 the results of this trial showed that the 
use of a high-dose intravenous iron regimen 
administered proactively was superior to the use 
of a low-dose intravenous iron regimen adminis-
tered reactively and was associated with a lower 
risk of death or major adverse cardiovascular 
events. Patients who had been assigned to re-
ceive high-dose iron therapy were less likely to 
have a myocardial infarction or be hospitalized for 
heart failure than those who had been assigned 
to receive low-dose iron therapy. In addition, 
high-dose iron administered proactively appeared 
to protect against recurrent events. Although iron 
therapy has been associated with a lower risk of 
cardiovascular events in placebo-controlled trials 
involving patients with heart failure,25-28 such 
benefits have not been observed in an incident 
dialysis population (with a baseline prevalence 
of heart failure of <5%). Furthermore, patients 
who received high-dose iron therapy had fewer 
blood transfusions and received lower doses of 
erythropoiesis-stimulating agents to maintain tar-
get hemoglobin levels than those in the low-dose 
group; patients in the high-dose group also had 
a faster increase in the hemoglobin level.
The cardiovascular safety profile that is associ-
ated with the use of high-dose intravenous iron 
therapy to maintain a target hemoglobin level is 
notable, given the safety concerns about using 
higher doses of erythropoiesis-stimulating agents 
to elevate the hemoglobin level. We speculate that 
the dose-sparing effect of intravenous iron ther-
apy on erythropoiesis-stimulating agents might 
contribute to the cardiovascular profile of high-
dose iron therapy that was observed in this trial. 
It is also possible that iron replacement in pa-
tients with iron deficiency has direct cardiovas-
cular benefits.
The absence of a greater risk of infection with 
the proactive, high-dose intravenous iron regi-
men is important, given studies that have sug-
gested that iron might potentiate bacterial 
growth and infection.12,29-32 In our trial, the in-
vestigators were advised to discontinue iron 
therapy in patients during episodes of infection.
The most appropriate intravenous iron-replace-
ment regimen in adults undergoing dialysis is 
unknown, which has resulted in different local, 
national, and international recommendations and 
practices. Observational studies have raised con-
cern that monthly doses of 300 mg or more of 
intravenous iron are associated with poor out-
comes.19-21 In the high-dose group of our trial, 
we used a monthly dose of 400 mg, with a per-
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protocol temporary discontinuation of treatment 
only if the ferritin concentration exceeded 700 μg 
per liter or the transferrin saturation was 40% or 
higher. Patients in the high-dose group received 
approximately twice the amount of iron as those 
in the low-dose group over the first year of the 
trial and 83.5% more iron per month over the 
course of the trial. The median monthly dose of 
iron that was administered in the high-dose group 
was 264 mg, which is greater than the approxi-
mately 218-mg dose that was reported by the 
Dialysis Outcomes and Practice Patterns Study in 
the United States.33 Given the improved outcomes 
that were observed with the high-dose intrave-
nous iron regimen in our trial, the safety and 
efficacy of even higher doses of iron might be 
explored in further trials.
The strengths of our trial include its size and 
Event
Proactive, High-Dose 
Iron Regimen 
(N = 1093)
Reactive, Low-Dose 
Iron Regimen 
(N = 1048)
no. of patients with event (%)
Any serious adverse event 709 (64.9) 671 (64.0)
Infection or infestation 341 (31.2) 327 (31.2)
Injury, poisoning, or procedural complication 220 (20.1) 224 (21.4)
Cardiac disorder 154 (14.1) 165 (15.7)
General disorder or administration-site condition 159 (14.5) 129 (12.3)
Respiratory, thoracic, or mediastinal disorder 107 (9.8) 121 (11.5)
Gastrointestinal disorder 111 (10.2) 110 (10.5)
Surgical or medical procedure 117 (10.7) 102 (9.7)
Metabolism or nutrition disorder 95 (8.7) 116 (11.1)
Vascular disorder 90 (8.2) 104 (9.9)
Nervous system disorder 98 (9.0) 82 (7.8)
Renal or urinary disorder 34 (3.1) 48 (4.6)
Investigation† 33 (3.0) 44 (4.2)
Musculoskeletal or connective-tissue disorder 28 (2.6) 37 (3.5)
Neoplasm, benign, malignant, or unspecified, including cysts 
and polyps
27 (2.5) 27 (2.6)
Psychiatric disorder 21 (1.9) 26 (2.5)
Hepatobiliary disorder 23 (2.1) 18 (1.7)
Skin or subcutaneous-tissue disorder 22 (2.0) 14 (1.3)
Blood or lymphatic system disorder 14 (1.3) 17 (1.6)
Reproductive system or breast disorder 2 (0.2) 7 (0.7)
Eye disorder 2 (0.2) 6 (0.6)
Social circumstance‡ 2 (0.2) 3 (0.3)
Immune system disorder 3 (0.3) 0
Congenital, familial, or genetic disorder 1 (0.1) 0
Ear or labyrinth disorder 0 1 (0.1)
Endocrine disorder 1 (0.1) 0
*  Data are the numbers and percentages of patients who had a serious adverse event, according to Medical Dictionary for 
Regulatory Activities, version 15.1, system organ class.
†  Investigation was defined as results of a laboratory test or other medical investigation that met the requirements for a 
serious adverse event.
‡  Social circumstance was defined as an event of medical relevance to the evaluation of other data (e.g., hospitalization 
for social reasons, such as general deterioration in health that led to an inability to function at home).
Table 3. Serious Adverse Events.*
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long duration of follow-up, the collection and 
adjudication of important clinical events, and the 
limited exclusion criteria that allowed for the en-
rollment of a cohort of patients representative of 
those seen in routine clinical practice. Limita-
tions of the trial include the restriction of the 
trial sites to a single country. Thus, the general-
izability of the trial findings to dialysis popula-
tions worldwide is unclear. The open-label nature 
of the trial may have potentially biased the rates 
of blood transfusion. Ongoing iron losses that 
have been associated with hemodialysis, com-
bined with the iron-storage capacity of the re-
ticuloendothelial system and the withholding of 
iron in patients with markedly elevated iron in-
dexes (ferritin concentration of >700 μg per liter 
or transferrin saturation of ≥40%), were expected 
to reduce the risk of overt toxic effects of iron in 
this population.1 However, the safety of this 
high-dose iron regimen cannot be confirmed 
beyond the duration of the current trial. Finally, 
because quality-of-life data were missing for 
many patients, the interpretation of the effect of 
the iron dose with regard to these end points is 
limited.
In conclusion, this trial showed that, among 
patients undergoing hemodialysis, the use of a 
high-dose regimen of intravenous iron adminis-
tered proactively resulted in a significantly lower 
risk of death or major nonfatal cardiovascular 
events as compared with that observed with a 
reactive, low-dose regimen. This dosing strategy 
also resulted in a significantly lower dose of 
erythropoiesis-stimulating agent and a lower inci-
dence of blood transfusion, whereas the incidence 
of infection and hospitalization for any cause did 
not differ significantly between the two treat-
ment groups.
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